Halozyme Therapeutics Inc
(NAS:HALO)
$
59.35
-0.26 (-0.44%)
Market Cap: 7.55 Bil
Enterprise Value: 8.42 Bil
PE Ratio: 19.65
PB Ratio: 16.67
GF Score: 88/100 Halozyme Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 02:50PM GMT
Release Date Price:
$38.92
(+3.79%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
All right. Welcome, everyone. This is the fireside chat with Halozyme. Thanks for joining us. My name is Vikram Purohit, I'm one of the biotech analysts with the research team. Before we start, let me read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. With that, Happy to have with me Helen Torley, CEO of Halozyme. Helen, thank you for joining us.
Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director
Appreciate the opportunity.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
So we have around 30 minutes, quite a bit in Halozyme's portfolio to unpack. But before we get into any specifics,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot